No. After. Here's the original post #43920 : >> New DNDN survey: Q: Given the outcome of the advisory panel today, what is your expectation for the FDA’s action on the Provenge BLA? a) Approval (or an approvable letter with minor conditions such as labeling). b) Approvable letter deferring a final decision until the outcome of the 9902b study is known. <<